|
1
|
Chen X, Zhang Y, Shi Y, Lian H, Tu H, Han
S, Peng B, Liu W and He X: miR-873 acts as a novel sensitizer of
glioma cells to cisplatin by targeting Bcl-2. Int J Oncol.
47:1603–1611. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Han L, Liu D, Li Z, Tian N, Han Z, Wang G,
Fu Y, Guo Z, Zhu Z, Du C and Tian Y: HOXB1 is a tumor suppressor
gene regulated by miR-3175 in glioma. PLoS One. 10:e01423872015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bageritz J, Puccio L, Piro RM, Hovestadt
V, Phillips E, Pankert T, Lohr J, Herold-Mende C, Lichter P and
Goidts V: Stem cell characteristics in glioblastoma are maintained
by the ecto-nucleotidase E-NPP1. Cell Death Differ. 21:929–940.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yuan L, Yuan P, Yuan H, Wang Z, Run Z,
Chen G, Zhao P and Xu B: miR-542-3p inhibits colorectal cancer cell
proliferation, migration and invasion by targeting OTUB1. Am J
Cancer Res. 7:159–172. 2017.PubMed/NCBI
|
|
5
|
Winter J, Jung S, Keller S, Gregory RI and
Diederichs S: Many roads to maturity: microRNA biogenesis pathways
and their regulation. Nat Cell Biol. 11:228–234. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fujii T, Shimada K, Tatsumi Y, Hatakeyama
K, Obayashi C, Fujimoto K and Konishi N: microRNA-145 promotes
differentiation in human urothelial carcinoma through
down-regulation of syndecan-1. BMC Cancer. 15:8182015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hata A and Lieberman J: Dysregulation of
microRNA biogenesis and gene silencing in cancer. Sci Signal.
8:re3. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lai NS, Wu DG, Fang XG, Lin YC, Chen SS,
Li ZB and Xu SS: Serum microRNA-210 as a potential noninvasive
biomarker for the diagnosis and prognosis of glioma. Br J Cancer.
112:1241–1246. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang GB, Liu JH, Hu J and Xue K: miR-21
enhanced glioma cells resistance to carmustine via decreasing Spry2
expression. Eur Rev Med Pharmacol Sci. 21:5065–5071.
2017.PubMed/NCBI
|
|
10
|
Zhi T, Yu T, Pan M, Nie E, Wu W, Wang X,
Liu N, You Y, Wang Y and Zhang J: EZH2 alteration driven by
microRNA-524-5p and microRNA-324-5p promotes cell proliferation and
temozolomide resistance in glioma. Oncotarget. 8:96239–96248. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen W, Yang Y, Chen B, Lu P, Zhan L, Yu
Q, Cao K and Li Q: miR-136 targets E2F1 to reverse cisplatin
chemosensitivity in glioma cells. J Neurooncol. 120:43–53. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Guo Y, Yan K, Fang J, Qu Q, Zhou M and
Chen F: Let-7b expression determines response to chemotherapy
through the regulation of cyclin D1 in glioblastoma. J Exp Clin
Cancer Res. 32:412013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Luo C, Yin D, Zhan H, Borjigin U, Li C,
Zhou Z, Hu Z, Wang P, Sun Q, Fan J, et al: microRNA-501-3p
suppresses metastasis and progression of hepatocellular carcinoma
through targeting LIN7A. Cell Death Dis. 9:5352018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sanches JGP, Xu Y, Yabasin IB, Li M, Lu Y,
Xiu X, Wang L, Mao L, Shen J, Wang B, et al: miR-501 is upregulated
in cervical cancer and promotes cell proliferation, migration and
invasion by targeting CYLD. Chem Biol Interact. 285:85–95. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang BS, Luo QZ, Han Y, Huang D, Tang QP
and Wu LX: miR-223/PAX6 axis regulates glioblastoma stem cell
proliferation and the chemo resistance to TMZ via regulating
PI3K/Akt pathway. J Cell Biochem. 118:3452–3461. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tian T, Mingyi M, Qiu X and Qiu Y:
MicroRNA-101 reverses temozolomide resistance by inhibition of
GSK3β in glioblastoma. Oncotarget. 7:79584–79595. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xiao S, Yang Z, Qiu X, Lv R, Liu J, Wu M,
Liao Y and Liu Q: miR-29c contribute to glioma cells temozolomide
sensitivity by targeting O6-methylguanine-DNA methyltransferases
indirectely. Oncotarget. 7:50229–50238. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liao H, Bai Y, Qiu S, Zheng L, Huang L,
Liu T, Wang X, Liu Y, Xu N, Yan X and Guo H: miR-203 downregulation
is responsible for chemoresistance in human glioblastoma by
promoting epithelial-mesenchymal transition via SNAI2. Oncotarget.
6:8914–8928. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang Y, Wu J, Guan H, Cai J, Fang L, Li J
and Li M: miR-136 promotes apoptosis of glioma cells by targeting
AEG-1 and Bcl-2. FEBS Lett. 586:3608–3612. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Qin XY, Suzuki H, Honda M, Okada H, Kaneko
S, Inoue I, Ebisui E, Hashimoto K, Carninci P, Kanki K, et al:
Prevention of hepatocellular carcinoma by targeting MYCN-positive
liver cancer stem cells with acyclic retinoid. Proc Natl Acad Sci
USA. 115:4969–4974. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang W, Liu B, Wu W, Li L, Broom BM,
Basourakos SP, Korentzelos D, Luan Y, Wang J, Yang G, et al:
Targeting the MYCN-PARP-DNA damage response pathway in
neuroendocrine prostate cancer. Clin Cancer Res. 24:696–707. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang T, Liu L, Chen X, Shen Y, Lian G,
Shah N, Davidoff AM, Yang J and Wang R: MYCN drives glutaminolysis
in neuroblastoma and confers sensitivity to an ROS augmenting
agent. Cell Death Dis. 9:2202018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Estiar MA, Javan F, Zekri A, Mehrazin M
and Mehdipour P: Prognostic significance of MYCN gene amplification
and protein expression in primary brain tumors: Astrocytoma and
meningioma. Cancer Biomark. 19:341–351. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bjerke L, Mackay A, Nandhabalan M, Burford
A, Jury A, Popov S, Bax DA, Carvalho D, Taylor KR, Vinci M, et al:
Histone H3.3. mutations drive pediatric glioblastoma through
upregulation of MYCN. Cancer Discov. 3:512–519. 2013. View Article : Google Scholar : PubMed/NCBI
|
